Abstract:Purpose of Review
Seizures, including status epilepticus, have been reported in association with acute COVID-19 infection. People with epilepsy (PWE) have suffered from seizure exacerbations during the pandemic. This article reviews the data for clinical and electrographic seizures associated with COVID-19, technical EEG considerations for reducing risk of transmission, and factors contributing to seizure exacerbations in PWE as well as strategies to address this issue.
Recent Findi… Show more
“…10,12,17-30 The frequency of new onset seizures in hospitalized COVID-19 patients who had EEG performed was 8.49% (95% confidential interval: .62-24.07, I 2 = 14%, 44/535 patients) (Figure 3). 31–38 The detailed description of studies utilized for the meta-analysis can be found in supplemental Table S2, which also includes clinical characteristics and diagnostic findings for these subjects.Figure 2.Frequency of new onset seizures in hospitalized COVID-19 patients.Figure 3.Frequency of seizures in COVID-19 patients for whom EEG monitoring was performed.…”
Section: Resultsmentioning
confidence: 99%
“…10,12,[17][18][19][20][21][22][23][24][25][26][27][28][29][30] The frequency of new onset seizures in hospitalized COVID-19 patients who had EEG performed was 8.49% (95% confidential interval: .62-24.07, I 2 = 14%, 44/535 patients) (Figure 3). [31][32][33][34][35][36][37][38] The detailed description of studies utilized for the meta-analysis can be found in supplemental Table S2, which also includes clinical characteristics and diagnostic findings for these subjects.…”
Objective Seizures in COVID-19 patients continue to be a common reason for consulting the neurology service in the inpatient setting. This paper assesses the frequency of new onset seizures in adult hospitalized COVID-19 patients. Method PubMed and EMBASE were searched, with fifteen cohort studies identified to calculate the primary outcome, which was the frequency of new onset seizures in hospitalized COVID-19 patients. An inverse variance meta-analysis of single proportions with a random effects model was applied to these cohort studies to calculate the primary outcome. Risk of bias in individual studies was assessed using the 10-item risk of bias tool for prevalence studies. Results The meta-analysis revealed a frequency of .71% (95% confidential interval: .32-1.25, I2 = 89%, 147/28242 patients) for acute symptomatic seizures in patients with COVID-19. For secondary outcomes, the risk of seizures in patients who had EEG completed was 8.49% (95% confidential interval: .62-24.07, I2 = 14%, 44/535 patients). Slightly less than half of patients with COVID-19 and seizures were reported to have acute imaging abnormalities (45.7%) with acute vascular insults being commonly reported. Only a small percentage of COVID-19 patients with seizures (2.8%) met the criteria for COVID-19 encephalitis as determined by the international encephalitis consortium. Conclusion The frequency of seizures in COVID-19 was .71% (95% confidential interval: .32-1.25). Slightly less than half of COVID-19 patients had head imaging abnormalities as a complication of COVID-19 infection. Only a small percentage of patients with seizures and COVID-19 met the criteria for COVID-19 encephalitis.
“…10,12,17-30 The frequency of new onset seizures in hospitalized COVID-19 patients who had EEG performed was 8.49% (95% confidential interval: .62-24.07, I 2 = 14%, 44/535 patients) (Figure 3). 31–38 The detailed description of studies utilized for the meta-analysis can be found in supplemental Table S2, which also includes clinical characteristics and diagnostic findings for these subjects.Figure 2.Frequency of new onset seizures in hospitalized COVID-19 patients.Figure 3.Frequency of seizures in COVID-19 patients for whom EEG monitoring was performed.…”
Section: Resultsmentioning
confidence: 99%
“…10,12,[17][18][19][20][21][22][23][24][25][26][27][28][29][30] The frequency of new onset seizures in hospitalized COVID-19 patients who had EEG performed was 8.49% (95% confidential interval: .62-24.07, I 2 = 14%, 44/535 patients) (Figure 3). [31][32][33][34][35][36][37][38] The detailed description of studies utilized for the meta-analysis can be found in supplemental Table S2, which also includes clinical characteristics and diagnostic findings for these subjects.…”
Objective Seizures in COVID-19 patients continue to be a common reason for consulting the neurology service in the inpatient setting. This paper assesses the frequency of new onset seizures in adult hospitalized COVID-19 patients. Method PubMed and EMBASE were searched, with fifteen cohort studies identified to calculate the primary outcome, which was the frequency of new onset seizures in hospitalized COVID-19 patients. An inverse variance meta-analysis of single proportions with a random effects model was applied to these cohort studies to calculate the primary outcome. Risk of bias in individual studies was assessed using the 10-item risk of bias tool for prevalence studies. Results The meta-analysis revealed a frequency of .71% (95% confidential interval: .32-1.25, I2 = 89%, 147/28242 patients) for acute symptomatic seizures in patients with COVID-19. For secondary outcomes, the risk of seizures in patients who had EEG completed was 8.49% (95% confidential interval: .62-24.07, I2 = 14%, 44/535 patients). Slightly less than half of patients with COVID-19 and seizures were reported to have acute imaging abnormalities (45.7%) with acute vascular insults being commonly reported. Only a small percentage of COVID-19 patients with seizures (2.8%) met the criteria for COVID-19 encephalitis as determined by the international encephalitis consortium. Conclusion The frequency of seizures in COVID-19 was .71% (95% confidential interval: .32-1.25). Slightly less than half of COVID-19 patients had head imaging abnormalities as a complication of COVID-19 infection. Only a small percentage of patients with seizures and COVID-19 met the criteria for COVID-19 encephalitis.
“…La encefalopatía por infección de SARS-COV-2 se debe a varios factores, tales como hipoxia, inducida por corticoides, falla multiorgánica e hiperinflamación sistémica. Estos pacientes presentan delirio hipoactivo como delirio hiperactivo (agitación, cambios de humor e irritabilidad), que no tienen (57)(58)(59)(60) una adecuada respuesta a los antipsicóticos .…”
Este es un artículo publicado en acceso abierto bajo una Licencia Creative Commons CC-BY 4.0
Manifestaciones neurológicas en pacientes con diagnóstico de COVID-19Neurological manifestations in patients diagnosed with COVID-19
“…The common cranial imaging and EEG findings in coronavirus infection with FS were not different from those in patients in the control group. New-onset epilepsy is rare in coronavirus infections, and the high risk of epileptic seizure is in those with seizure-like events and those with pre-existing epilepsy or brain injury (Pellinen & Holmes, 2022). Both groups of patients were followed for 3 months, and only one patient in each group had one recurrence of febrile seizures.…”
The study of children who experienced with febrile seizures(FS) as a result of COVID-19 infection to gain insight into the clinical characteristics and prognosis of neurological damage, with the aim of improving prevention, diagnosis, and the treatment of neurological complications. This study investigated the clinical features of 53 children with FS who were admitted to Sanya Women and Children's Hospital from December 1, 2022, to January 31, 2023. The results indicated that the duration of convulsion in the case and control group was 7.90±8.91 and 2.67±1.23 (minutes) respectively. The analysis reveals that convulsions occurred within 24 hours in 39 cases (95.12%) of the case group, and in 8 cases (66.7%) of the control group. The difference was statistically significant (P<0.05). Additionally, the case group presented lower counts of WBC and NEU compared to the control group (p<0.05). The findings indicate that convulsions manifest at earlier stages of COVID-19 in children and the last longer than in the control group. It is therefore crucial for healthcare workers to remain attentive to patients with COVID-19 who report fever within 24 hours, and act promptly to implement preventive measures, particularly in cases of prolonged fever. It is essential to integrate the clinical manifestation, particularly convulsions, and the continuous numerical changes of inflammatory factors to assess COVID-19 linked with febrile seizures. In addition, larger-scale multi-center and systematic research are necessary to aid clinicians in monitoring neuropathological signals and biological targets, enabling more equitable diagnosis and treatment plans.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
